Lightchain Capital



Arch Oncology, Inc.

(Brisbane, CA, and St. Louis, MO) – A privately-held, clinical-stage immuno-oncology company aiming to discover and develop potential best-in-class antibody therapies for the treatment of cancer patients.


C4 Therapeutics, Inc.

(Watertown, MA) – A clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation.


Geneoscopy, Inc.

(St. Louis, MO) – A life sciences company focused on developing a broad portfolio of non-invasive, safe, effective and innovative gastrointestinal-related diagnostics to improve the diagnosis, treatment and monitoring of gastrointestinal diseases. This includes cancer screening compliance to facilitate early-stage detection.


MANA Therapeutics

(Waltham, MA) – A clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens. MANA’s proprietary EDIFYÔ platform harnesses natural immune system pathways to educate T-cells to target tumor-associated antigens.


NextRNA Therapeutics

(Cambridge, MA) – A newly-founded biotechnology company committed to developing the next wave of RNA-targeted therapeutics. Innovative discovery platform identifies and modulates the RNA binding protein responsible for the disease function of a non-coding RNA “ncRNA.”



(St. Louis, MO and San Diego, CA) – A clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer. Proprietary technology to manufacture universal “off-the-shelf” Memory NK and CAR-T cells for the treatment of solid tumors, T-cell malignancies, Acute Myeloid Leukemia, and multiple myeloma.



(St. Louis, MO) – CareVet is a veterinary practice management group that manages and supports best-in-class hospitals throughout the US.


Simple Rose

(St. Louis, MO) - Applications include scheduling, production planning, and portfolio optimization, solving high-value problems that result in hundreds of millions of dollars of improvement to our customers' bottom line.